DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient
Cristina R. Antonescu, Victor E. Reuter, Mary Lou Keohan, Sinchun Hwang, Ping Chi
Abstract
Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.21.00554 JCO Precision Oncology no. 6 (2022) e2100554. Published online July 7, 2022. PMID: 35797510 DICER1-Associated Anaplastic Sarcoma of the Kidney With Coexisting Activating PDGFRA D842V Mutations and Response to Targeted Kinase Inhibitors in One Patient Cristina R. Antonescu , MD1xCristina R. AntonescuSearch for articles by this author; Victor E. Reuter, MD1xVictor E. ReuterSearch for articles by this author; Mary Lou Keohan, MD2xMary Lou KeohanSearch for articles by this author; Sinchun Hwang , MD3xSinchun HwangSearch for articles by this author; and Ping Chi , MD, PhD2,4,5xPing ChiSearch for articles by this author Show More 1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY3Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY5Department of Medicine, Weill Cornell Medical College, New York, NY https://doi.org/10.1200/PO.21.00554 First Page Full Text PDF Figures and Tables Supplements © 2022 by American Society of Clinical OncologySUPPORTSupported by grants from the National Institute of Health/National Cancer Institute (Cancer Center Support Grant No. P30CA008748 to C.R.A. and P.C.; Sarcoma SPORE P50CA217694 to C.R.A. and P.C.), Cycle for Survival and Geoffrey Beene Research Fund to P.C., and Kristin Ann Carr Foundation to C.R.A.AUTHOR CONTRIBUTIONSConception and design: Cristina R. Antonescu, Ping ChiFinancial support: Ping ChiAdministrative support: Ping ChiProvision of study materials or patients: Victor E. Reuter, Mary Lou Keohan, Ping ChiCollection and assembly of data: All authorsData analysis and interpretation: Cristina R. Antonescu, Mary Lou Keohan, Sinchun Hwang, Ping ChiManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Victor E. ReuterConsulting or Advisory Role: CepheidUncompensated Relationships: PAIGE.AIPing ChiStock and Other Ownership Interests: ORIC Pharmaceuticals (I)Consulting or Advisory Role: Deciphera, NewBay Pharma, Zai LabResearch Funding: Deciphera (Inst), Pfizer (Inst), NewBay Pharma (Inst)Patents, Royalties, Other Intellectual Property: Royalties from ORIC (I)No other potential conflicts of interest were reported.